Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Imprimis receives FDA warning

The U.S. FDA issued a warning letter to Imprimis Pharmaceuticals Inc. accusing it of making false or misleading claims that its compounded eye medications had the agency’s approval.

Read More »

Future of Kala Pharma’s dry eye drug uncertain after mixed results

Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc.’s drug to provide temporary relief from dry eye disease cast doubt on the drug’s path forward.

Read More »

Drugmakers raise 2018 U.S. prices

2018 opened with elevated U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit.

Read More »

FDA Accepts Sun Pharma’s NDA for OTX-101

Sun Pharmaceutical Industries Ltd. announced the U.S. FDA accepted a New Drug Application (NDA) for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%.

Read More »

Allergan tries to assuage shareholder fears over Restasis

Allergan Plc tried to reassure shareholders after losing a major patent ruling during October 2017 on its second-most important drug, the dry-eye treatment Restasis, downplaying the importance of the loss of revenue from the drug.

Read More »

Imprimis Pharma to take on Allergan’s Restasis with cheaper product

Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent after the company said it would offer a cheaper option to Allergan’s dry eye disease medicine Restasis.

Read More »

Allergan ruling casts doubt on tribal patent strategy

A U.S. judge’s ruling invalidating Allergan Plc’s patents on its blockbuster $1.5 billion dry-eye medicine Restasis has cast doubt on the company’s novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

Read More »

Allergan settles with one of four companies contesting Restasis patent

Allergan Plc said it reached a settlement with InnoPharma Inc., one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

Read More »

Shire sues Allergan in U.S. over dry eye drug

Allergan Plc was sued by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease.

Read More »

Native American tribe moves to dismiss Allergan patent case

A Native American tribe holding patents for drugmaker Allergan Plc moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom